Kymera Results Presentation Deck

KT-333: Phase 1, Multicenter, Dose-Escalation and Expansion Trial to Evaluate KT-333 in Adult Patients with PTCL, CTCL, LGL-L, and Solid Tumors 0.05 Primary Dec. 2022: Currently enrolling Key Objectives Secondary 0.10 ● ● ● Phase 1a (n up to 40) R/R Lymphoma/Leukemia or Solid Tumors Regimen: mg/kg IV Infusion weekly 0.20 0.40 DLX Predicted clinically efficacious doses Phase 1a Safety/Tolerability and MTD and RP2D PK Parameters of KT-333 Preliminary Estimates of Activity Exploratory PD Effects of KT-333 MTD: Maximum Tolerated Dose. RP2D: Recommended Phase 2 Dose. ORR: Overall Response Rate KYMERA ©2022 KYMERA THERAPEUTICS, INC. ● ● MTD/RP2D Expansion* ● Phase 1b (n=40) Cohort 1: PTCL n=20 Phase 1b • Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors Cohort 2: CTCL n=20 PD Effects of KT-333 Cohort 3: LGL-L n=20 Cohort 4: Solid Tumors n=20 Preliminary Clinical Activity (ORR, DOR, PFS, DCR, OS) PK Parameters of KT-333 PAGE 10

View entire presentation